RxDoctor Payments Data

Ramni Khattar, DO

Pulmonary Disease · Escondido, CANPI 1225423619

Payments from drug & device makers

$2,294in general payments, 2019–2025

Across 70 payments — averaging $32.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$1K
  • United Therapeutics Corporation$244
  • AstraZeneca$214
  • GSK$166
  • Olympus America Inc.$153
  • Inari Medical, Inc.$152
  • plus $351 from 12 others

What the payments were for

  • Food & beverage$2,27399%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,294 in reported general payments places this provider in the 55th percentile of 1,261 pulmonary disease providers in California.

See all pulmonary disease providers in California

Medicare billing

Part B allowed, 2024
$169,066
Medicare patients
624
Services billed
1,784

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban28$23,767
Stiolto RespimatTiotropium Br/Olodaterol Hcl35$21,209
Spiriva RespimatTiotropium Bromide17$9,125
BreynaBudesonide/Formoterol Fumarate45$8,374
SymbicortBudesonide/Formoterol Fumarate13$3,491
Arnuity ElliptaFluticasone Furoate13$2,402
Azelastine Hcl60$2,021
Wixela InhubFluticasone Propion/Salmeterol12$1,823
Albuterol Sulfate HfaAlbuterol Sulfate39$1,325
Fluticasone Propionate73$985
Rifampin11$187
Prednisone30$140
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav14$97
Omeprazole21$84
Azithromycin14$63

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$1,014$30,33352 claims
AstraZenecaSymbicort$214$3,49113 claims
GSKArnuity Ellipta$166$2,40213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,261 pulmonary disease providers in California.

Other pulmonary disease in Escondido

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →